The ability of CD44 expression in biopsies and transurethral resections to predict tumor aggressiveness in prostatectomies had been evaluated [37, 38], as had the association of biopsies and transurethral resections with anatomopathological factors and tumor progression [39–41]. Here, CD44 is linked to neoplasm.